Antengene Corporation Limited announced that the Department of Health, the Government of the Hong Kong Special Administrative Region (HKSAR) has approved a New Drug Application (NDA) for XPOVIO®? (selinexor), applicable in combination with dexamethasone (Xd), for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), two immunomodulatory agents (IMiDs), an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. XPOVIO®?

is the world's first oral selective inhibitor of the nuclear export protein (XPO1), with regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdom, the European Union (the 27 member countries including France and Italy), Canada, Norway, Iceland, Lichtenstein, South Korea, mainland of China, Taiwan China, Hong Kong China, Singapore, Australia and Northern Ireland. To date, 6 XPOVIO®?regimens received a total of 27 inclusions into 7 clinical guidelines of major oncology societies in the U.S., the EU, and APAC, including 5 regimens for the treatment of myeloma and 1 regimen for the treatment of lymphoma added to the guidelines of the National Cancer Care Network (NCCN); 4 regimens for the treatment ofMyeloma and 1 regimen for The treatment of lymphoma added to The Chinese Society of Clinical Oncology (CSCO); 5 regimens for the treatment the treatment of myeloma added to the guidelines for the Diagnosis and Management of Multiple Myeloma in China; 4 regimens for the treatment thetreatment of myeloma added to The China Anti-Cancer Association's Guidelines for the Holistic lntegrative Management of Cancers (CACA); 2 regimens for the treatment of Myeloma added to the guidelines of The European Society of Medical Oncology (ESMO); and 1 regimen for the treatment the treatment of Myeloma added to the Guidelines of the International Myeloma Working Group (IMWG).